PET/CT imaging of skeletal muscle metastases

Abstract

Skeletal muscle metastases (SMM) are very rare because of complex resistance of the musculature to metastatic invasion. Previously, positron emission tomography (PET) imaging of SMM has been reported only in few reports. A systematic analysis of SMM features in PET/CT has not been performed before. To study PET/CT findings of SMM in a larger group of patients with known malignancies and to determine PET/CT patterns of SMM in different primary tumors. Between January 2009 and December 2011 581 patients with lung cancer were investigated by PET with 18 F-fluordeoxyglucose (FDG PET) and computed tomography (CT) at the Center of Fusion Imaging, Halle. In five patients SMM were identified. Furthermore, PubMed database was screened for muscle metastases. Only articles containing SUV of SMM were considered in the study. Twenty-one articles with 33 patients could be included in this meta-analysis from the literature. At our center the prevalence of SMM was 0.9%. Our analysis comprised 38 patients with 67 muscle metastases. All identified SMM presented as intramuscular focal abnormal activity with SUV ranging from 2.4 to 25.9, median SUV 7.8. The median size of the muscle metastases was 2.5 cm (range, 0.6-6.5 cm). There were no significant differences between SUV and size of SMM arising from lung cancer, renal cell carcinoma, and esophageal cancer. Also, there was no correlation between SUV and size of SMM (r = 0.101, P = 0.558) and between SUV of SMM and primary tumors (r = 0.138, P = 0.686). In nine (23.7%) of the 38 patients, the identified SMM were isolated distant metastases or isolated tumor recurrence. SMM manifested on PET/CT as focal hypermetabolic intramuscular areas with different SUV. There were no significant differences between SUV or size of the identified SMM in esophageal cancer, renal cell carcinoma, and lung cancer.